Back to Journals » Vascular Health and Risk Management » Volume 13
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
7,887 | Dovepress* | 6,790+ | 1,627 | 8,417 | |
PubMed Central* | 1,097 | 307 | 1,404 | ||
Totals | 7,887 | 1,934 | 9,821 | ||
*Since 6 July 2017 |
View citations on PubMed Central and Google Scholar